Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Jun 21, 2023
TickeronGET DAILY SIGNALS

AI Trading Bot Triumph: TLRY strong performance, Swing Trading High-Volatility Stocks

AI Trading Bot Yields Impressive strong performance for TLRY Amid High Volatility Market Scenario

The rapidly advancing technology of Artificial Intelligence (AI) is becoming an undeniable game-changer in the financial sector, particularly in the stock trading realm. A prime example of this shift is the recent performance of an AI Trading Bot that generated an impressive strong performance on Tilray Inc. (TLRY), an internationally recognized cannabis company.

In the volatile, high-frequency trading environment that characterizes the modern stock market, this AI Trading Bot demonstrated exceptional resilience and strategic precision. Through machine learning algorithms, these automated systems can rapidly analyze vast amounts of data, from market trends to economic indicators, to make informed trading decisions in real time.

The AI bot's performance with TLRY shares significantly outperformed the broader market, highlighting the potential of such technology to optimize trading outcomes. It not only considers the quantitative data but also incorporates sentiment analysis, effectively monitoring and interpreting market emotions.

Alongside this, the Swing Trader's 'Top High-Volatility Stocks v.2 (TA)' portfolio experienced an astounding growth of 31.46%. This advanced swing trading model aims to take advantage of price swings in highly volatile securities, employing advanced technical analysis to forecast market movements.

The exceptional results of these AI-guided systems underscore the growing influence of machine learning and AI in reshaping the investment landscape, particularly amid market volatility.

On another note, investors and market watchers are eagerly anticipating Tilray's upcoming earnings report. TLRY is scheduled to report its earnings on October 6, 2023. These earnings reports are crucial indicators of a company's financial health and can significantly influence stock prices.

Whether you're a seasoned investor or just getting started, it's important to keep an eye on these sophisticated tools. The integration of AI into trading strategies is proving to be a successful approach, especially in managing high-volatility stocks. However, as with any investment strategy, it's crucial to remember that past performance is not a assure of future results.

The fusion of technology with finance, often referred to as FinTech, continues to evolve. The compelling performances of AI Trading Bots and other algorithm-based trading strategies underscore this evolution, highlighting the burgeoning role of AI in the financial sector. As we anticipate Tilray's earnings report, it's fascinating to speculate how AI might further transform our trading strategies and the broader financial landscape in the future.

Related Ticker: TLRY

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


TLRY's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for TLRY turned positive on November 04, 2026. Looking at past instances where TLRY's MACD turned positive, the stock continued to rise in 37 of 41 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TLRY's RSI Indicator exited the oversold zone, 40 of 50 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

Following a +16.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in 166 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 46 cases where TLRY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TLRY as a result. In 71 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TLRY entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.254) is normal, around the industry mean (6.379). P/E Ratio (-2.679) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (183.387).

The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -0%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 10%. XERS experienced the highest price growth at 53%, while AKAN experienced the biggest fall at -32%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 10%. For the same stocks of the Industry, the average monthly volume growth was 21% and the average quarterly volume growth was 16%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 55
Price Growth Rating: 61
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 3 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a holding company, whose subsidiaries engages in research, cultivation, processing and distribution of medical cannabis

Industry PharmaceuticalsGeneric

Industry
Biotechnology
Address
265 Talbot Street West
Phone
+1 844 845-7291
Employees
3595
Web
https://www.tilray.com
Interact to see
Advertisement
AtlasClear Holdings (ATCH) shares fell roughly 25.5% over the last 30 days, declining from $0.1881 on October 2 to $0.1401 on October 30. The pullback extended a longer downtrend that has kept the stock trading well below the $1.00 NYSE American minimum, keeping continued listing-compliance risk in focus.
The $1.14 central target is not an analyst consensus; it is the all-cash merger consideration in GoPro, Inc. (GPRO) 's pending deal with Starman Optical, agreed in September 2026. With the stock trading near $0.88, reaching $1.14 would require a move of roughly 29.5%.
The central target of $1,620 is the arithmetic mean of verified, current analyst price targets, rounded to a clean level; it is not a single firm's forecast or a guarantee. At a recent price of about $690 , reaching $1,620 would require a gain of roughly 135% , a very large move by any standard.
Nebius Group N.V. is expected to report third-quarter 2026 results in early November, following a second quarter in which revenue surged 454% year over year. Wall Street consensus tracked by Benzinga points to roughly $937 million in Q3 2026 revenue, up from $146.1 million in the year-ago quarter.
NVDA fell -2.10% to $216.66 during regular trading, down from a prior close of $221.30. Primary catalyst: hotter-than-expected September CPI data reignited Fed rate-hike fears, raising borrowing costs for AI infrastructure buildouts.